BioNTech's CTLA-4 Drug Nearly Doubles Survival in Lung Cancer Trial, But Raises Tolerability Concerns
- Gotistobart (BNT316/ONC-392), a CTLA-4-targeting monoclonal antibody from BioNTech and partner OncoC4, is designed to selectively deplete regulatory T cells within the tumor microenvironment.
- Updated stage 1 data from the global Phase 3 PRESERVE-003 trial were presented at the IASLC 2026 World Conference on Lung Cancer.
- The trial enrolled previously treated metastatic squamous non-small cell lung cancer (NSCLC) patients whose disease had progressed on prior immunotherapy and chemotherapy.
- Gotistobart nearly doubled median overall survival to 18.5 months versus 10.0 months for docetaxel chemotherapy, a statistically significant and clinically meaningful benefit (hazard ratio 0.56).
- Fierce Biotech's coverage noted the drug poses a tolerability challenge alongside this survival benefit.
- The pivotal stage 2 portion of PRESERVE-003 is ongoing at more than 160 sites worldwide.
CTLA-4 carries baggage — ipilimumab's toxicity effectively exiled the class to combo-backup duty, so gotistobart's whole pitch is "selective Treg depletion solves what ipi couldn't." A tolerability flag showing up in the very same headline as the efficacy win is the tension to watch, not a footnote. That said, nearly doubling median OS (18.5 vs 10.0 months, HR 0.56) in post-IO/chemo squamous NSCLC is a genuinely hard bar to clear — this is BioNTech's most credible non-mRNA oncology proof point yet, a real diversification lever beyond the vaccine franchise. It's also OncoC4's asset first: a clean stage 2 readout would meaningfully strengthen OncoC4's hand on deal economics with BioNTech, not just validate the science. Market-wise, the OS number is a legitimate re-rating catalyst, but "tolerability concerns" in the same breath keeps enthusiasm capped until discontinuation and grade 3+ rates surface from the pivotal cohort.
BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial but poses tolerability challenge ↗